Which pharmacies still compound it?
Many state-licensed 503A pharmacies; telehealth platforms typically partner with vetted networks.
What changed after October 2024?
503B production ended; 503A patient-specific continues.
Can I switch from compounded back to brand?
Yes, dose continuity is typically maintained.
How do I know my compounded tirzepatide is real?
Verify pharmacy licensure, USP 797 compliance, named source, and third-party testing.
What clinical reasons keep me eligible?
Allergen sensitivity, dose individualization, concentration adjustment, preservative-free needs.
Is FormBlends still providing it?
Yes, through 503A pharmacy partners with documented clinical justification.
Is there a quality difference between compounded and brand?
Different regulatory frameworks, same active ingredient, different manufacturing scale and trial backing.
Why does compounded cost more now than 2023?
Patient-specific 503A compounding has higher per-unit costs than batch production.
Will availability change again?
Possible; track new shortage declarations or regulatory changes.
Related guides
- Can You Still Get Compounded Tirzepatide? The Post-Shortage Reality
- Can You Still Get Compounded Semaglutide? The 2026 Reality
- What Insurance Covers Tirzepatide in 2026? The Diagnosis-Specific Answer
- How to Access Affordable Tirzepatide in 2026: Brand vs Compounded Cost Breakdown
- Mounjaro Injection Price Equivalent: What You'll Actually Pay for Brand vs Compounded Tirzepatide in 2026
- Where to Find the Cheapest Compounded Tirzepatide Without Sacrificing Quality in 2026
Sources
- FDA Drug Shortage List update, October 2, 2024
- Federal Food, Drug, and Cosmetic Act Section 503A, 21 U.S.C. § 353a
- Food and Drug Administration Modernization Act of 1997 (Pub. L. 105-115)
- USP General Chapter 797, Pharmaceutical Compounding - Sterile Preparations
- Outsourcing Facilities Association v. FDA ruling, March 5, 2025
- Jastreboff AM et al., "Tirzepatide Once Weekly for the Treatment of Obesity," NEJM, July 2022
- Eli Lilly LillyDirect platform information
- National Association of Boards of Pharmacy resources
- FDA Guidance on compounding under Section 503A
- Zepbound and Mounjaro FDA prescribing information
- State pharmacy board licensure databases (varies by state)
- FDA enforcement actions against non-licensed sources, 2024-2025
Footer disclaimers
Platform Disclaimer. FormBlends connects patients with licensed clinicians and 503A compounding pharmacies. We are not a pharmacy or a medical practice; clinical decisions and dispensing rest with licensed professionals.
Get compounded tirzepatide, first month $149, then $239 per month, or $214 per month with Subscribe & Save
Free provider review, personalized dosing, and ongoing support included.
Start Free Assessment →Compounded Medication Notice. Compounded tirzepatide is prepared by 503A pharmacy partners for individual patients based on prescriber-documented clinical reasons. Not FDA-approved. Not regulatorily equivalent to Mounjaro or Zepbound. SURMOUNT trial data applies to brand product.
Results Disclaimer. Individual outcomes vary. SURMOUNT-1 reported a 22.5% mean weight loss at the 15 mg dose over 72 weeks. Your result depends on dose, adherence, baseline weight, and individual response.
Trademark Notice. Mounjaro, Zepbound, LillyDirect, and SURMOUNT are trademarks or service marks of Eli Lilly and Company. FormBlends is independent.
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →